Tag: tocilizumab

COVID-19

A phase 2, open label, multicenter, single arm study of tocilizumabon the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical Analysis Plan

Publication date: 12/05/2020 – E&P Code: repo.epiprev.it/1610
Authors: Paolo Chiodini1, Laura Arenare2, Maria Carmela Piccirillo2, Francesco Perrone2, Ciro Gallo1

Abstract: Background. Tocilizumab, an IL-6 receptor antagonist, was suggested as a possible treatment of severe or critical COVID-19 pneumonia in a small Chinese study. The TOCIVID-19 trial evaluates efficacy and tolerability of tocilizumab in the treatment of patients with severe or critical COVID-19 pneumonia.
Methods/design. TOCIVID-19is an academic multicenter, single-arm, open-label, phase 2 study. All the patients are being offered a single shot of 8 mg/kg of Tocilizumab (up to a maximum of 800 mg), with an eventual second administration at the discretion of the Investigator. A companion prospective cohort includes either patients not eligible for phase 2 or subjects eligible for phase 2 but exceeding the planned sample size. 14- and 30-days lethality rates are the two co-primary endpoints in the intention-to-treat (ITT) population. Secondary objectives are to evaluate mortality and clinical improvement in the modified-ITT population of subjects who received the drug. Details of the methodological and statistical approaches are reported here reflecting the amendments impelled by the continuously increasing knowledge on COVID-19 progression and troubles in data collection.
Discussion. This paper provides details of planned statistical analyses for TOCIVID19 trial to reduce the risk of reporting bias and increase credibility of the study findings.
TOCIVID-19 trials registered in the EudraCT database with number 2020-001110-38 and in clinicaltrials.gov with ID NCT04317092.

More >
COVID-19

Multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia

Publication date: 12/05/2020 – E&P Code: repo.epiprev.it/1604
Authors: Maria Carmela Piccirillo1, Paolo Ascierto1, Luigi Atripaldi2, Marco Cascella1, Massimo Costantini3, Giovanni Dolci3-4, Nicola Facciolongo3, Fiorentino Fragranza2, AnnaMaria Marata5, Marco Massari3, Vincenzo Montesarchio2, Cristina Mussini4, Emanuele Alberto Negri3, Roberto Parrella2, Patrizia Popoli6, Gerardo Botti1, Laura Arenare1, Paolo Chiodini7, Ciro Gallo7, Carlo Salvarani3-4, Francesco Perrone1

Abstract: Background: Pneumonia is the most frequent and serious complication of COVID-19, due to an excessive and aberrant host immune response that is associated with an acute respiratory distress syndrome, with typical radiological findings and, in most critical patients, with a “cytokine storm”. IL-6 might play a key role in the cytokine storm induced bySARS-CoV-2 and interfering of IL-6 might be a potentially therapeutic strategy for severe and critical COVID-19. Tocilizumab is a recombinant humanized monoclonal antibody, directed against IL-6 receptor.

More >